LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.

    Walle, Thomas / Bajaj, Sunanjay / Kraske, Joscha A / Rösner, Thomas / Cussigh, Christiane S / Kälber, Katharina A / Müller, Lisa Jasmin / Strobel, Sophia Boyoung / Burghaus, Jana / Kallenberger, Stefan M / Stein-Thöringer, Christoph K / Jenzer, Maximilian / Schubert, Antonia / Kahle, Steffen / Williams, Anja / Hoyler, Birgit / Zielske, Lin / Skatula, Renate / Sawall, Stefanie /
    Leber, Mathias F / Kunes, Russell Z / Krisam, Johannes / Fremd, Carlo / Schneeweiss, Andreas / Krauss, Jürgen / Apostolidis, Leonidas / Berger, Anne Katrin / Haag, Georg M / Zschäbitz, Stefanie / Halama, Niels / Springfeld, Christoph / Kirsten, Romy / Hassel, Jessica C / Jäger, Dirk / Ungerechts, Guy

    Nature cancer

    2022  Volume 3, Issue 9, Page(s) 1039–1051

    Abstract: Patients with cancer frequently receive immune-checkpoint inhibitors (ICIs), which may modulate immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was observed in a patient with cancer who received BTN162b2 vaccination under ...

    Abstract Patients with cancer frequently receive immune-checkpoint inhibitors (ICIs), which may modulate immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was observed in a patient with cancer who received BTN162b2 vaccination under ICI treatment. Here, we analyzed adverse events and serum cytokines in patients with 23 different tumors undergoing (n = 64) or not undergoing (n = 26) COVID-19 vaccination under ICI therapy in a prospectively planned German single-center cohort study (n = 220). We did not observe clinically relevant CRS (≥grade 2) after vaccination (95% CI 0-5.6%; Common Terminology of Adverse Events v.5.0) in this small cohort. Within 4 weeks after vaccination, serious adverse events occurred in eight patients (12.5% 95% CI 5.6-23%): six patients were hospitalized due to events common under cancer therapy including immune related adverse events and two patients died due to conditions present before vaccination. Despite absence of CRS symptoms, a set of pairwise-correlated CRS-associated cytokines, including CXCL8 and interleukin-6 was >1.5-fold upregulated in 40% (95% CI 23.9-57.9%) of patients after vaccination. Hence, elevated cytokine levels are common and not sufficient to establish CRS diagnosis.
    MeSH term(s) COVID-19 ; COVID-19 Vaccines/adverse effects ; Cohort Studies ; Cytokine Release Syndrome ; Cytokines ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy/adverse effects ; Interleukin-6 ; Neoplasms/drug therapy ; Vaccination
    Chemical Substances COVID-19 Vaccines ; Cytokines ; Immune Checkpoint Inhibitors ; Interleukin-6
    Language English
    Publishing date 2022-06-17
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2662-1347
    ISSN (online) 2662-1347
    DOI 10.1038/s43018-022-00398-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.

    Walle, Thomas / Bajaj, Sunanjay / Kraske, Joscha A / Rösner, Thomas / Cussigh, Christiane S / Kälber, Katharina A / Müller, Lisa Jasmin / Strobel, Sophia Boyoung / Burghaus, Jana / Kallenberger, Stefan M / Stein-Thöringer, Christoph K / Jenzer, Maximilian / Schubert, Antonia / Kahle, Steffen / Williams, Anja / Hoyler, Birgit / Zielske, Lin / Skatula, Renate / Sawall, Stefanie /
    Leber, Mathias F / Kunes, Russell Z / Krisam, Johannes / Fremd, Carlo / Schneeweiss, Andreas / Krauss, Jürgen / Apostolidis, Leonidas / Berger, Anne Katrin / Haag, Georg M / Zschäbitz, Stefanie / Halama, Niels / Springfeld, Christoph / Kirsten, Romy / Hassel, Jessica C / Jäger, Dirk / Ungerechts, Guy

    Nature cancer

    2022  Volume 3, Issue 9, Page(s) 1137

    Language English
    Publishing date 2022-07-15
    Publishing country England
    Document type Published Erratum
    ISSN 2662-1347
    ISSN (online) 2662-1347
    DOI 10.1038/s43018-022-00420-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent but clinically inapparent in cancer patients under immune checkpoint therapy

    Walle, Thomas / Bajaj, Sunanjay / Kraske, Joscha A / Roesner, Thomas / Cussigh, Christiane Sophie / Kaelber, Katharina Anna / Mueller, Lisa Jasmin / Strobel, Sophia Boyoung / Burghaus, Jana / Kallenberger, Stefan / Stein-Thoeringer, Christoph / Jenzer, Maximilian / Schubert, Antonia / Kahle, Steffen / Williams, Anja / Hoyler, Birgit / Zielske, Lin / Skatula, Renate / Sawall, Stefanie /
    Leber, Mathias Felix / Kunes, Russell Z / Krisam, Johannes / Fremd, Carlo / Schneeweiss, Andreas / Krauss, Juergen / Berger, Anne Katrin / Haag, Georg Martin / Zschaebitz, Stefanie / Halama, Niels / Springfeld, Christoph / Kirsten, Romy / Hassel, Jessica C / Jaeger, Dirk / NCT ANTICIPATE Investigators / Ungerechts, Guy

    medRxiv

    Abstract: Cancer patients frequently receive immune checkpoint therapies (ICT) which may modulate immune responses to COVID-19 vaccines. Recently, a cytokine release syndrome (CRS) was observed in a cancer patient who received the BTN162b2 vaccine under ICT. Here, ...

    Abstract Cancer patients frequently receive immune checkpoint therapies (ICT) which may modulate immune responses to COVID-19 vaccines. Recently, a cytokine release syndrome (CRS) was observed in a cancer patient who received the BTN162b2 vaccine under ICT. Here, we analyzed adverse events (AEs) in patients of various solid tumor types undergoing (n=64) or not undergoing (n=26) COVID-19 vaccination under ICT as an exploratory endpoint of a prospectively planned cohort study. We did not observe clinically relevant CRS after vaccination (95% CI [0,0.056]). Short term (<4 weeks) serious AEs were rare (12.5%) and overall AEs under ICT were comparable to unvaccinated patients. Despite the absence of CRS symptoms, we observed a pairwise-correlated set of CRS-associated cytokines upregulated in 42% of patients after vaccination and ICT (>1.5fold). Hence, clinically meaningful CRS appears to be rare in cancer patients under ICT and elevated serum cytokine levels are common but not sufficient to establish CRS diagnosis.
    Keywords covid19
    Language English
    Publishing date 2021-12-11
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.12.08.21267430
    Database COVID19

    Kategorien

To top